Highlights GNI Group Ltd.

Equities

2160

JP3386370005

Delayed Japan Exchange Other stock markets 10:25:32 2024-06-02 pm EDT			5-day change	1st Jan Change
2,169 ^JPY	-1.54%		+3.93%	-23.39%

May. 31	Gyre Therapeutics Gets Investigational New Drug Application Approval in China for Pulmonary Arterial Hypertension Therapy	MT
Mar. 19	Jefferies Adjusts GNI Group’s Price Target to 4,100 Yen From 3,000 Yen, Keeps at Buy	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Gyre Therapeutics Gets Investigational New Drug Application Approval in China for Pulmonary Arterial Hypertension Therapy	May. 31	MT
GNI Group Ltd. Provides Consolidated Earnings Guidance for the Full Year Ending December 2024	Feb. 14	CI
GNI Group Revises Fiscal 2023 Forecast Upwards after Subsidiaries Show Better-than-Expected Sales, Foreign Exchange Rates	Nov. 05	MT
GNI Group Ltd. Revises Consolidated Earnings Guidance for the Full Year Ending December 31, 2023	Nov. 05	CI
GNI Group Plans to Buy Portion of Elutia's Orthobiologics Business	23-09-20	MT
North American Morning Briefing : Stock Futures Lack Momentum as Fed Decision Looms	23-09-19	DJ
Elutia Sells Orthobiologics Business Unit For Up to $35 Million	23-09-18	MT
GNI Subsidiary Cullgen Closes Series C Funding	23-08-23	MT
GNI Group Ltd. Revises Consolidated Earnings Guidance for the Year Ending December 31, 2023	23-08-03	CI
GNI Completes Investment in Shanghai JIUCE for China Expansion	23-08-02	MT
GNI Group Unit, Astellas Pharma Partner to Discover Innovative Protein Degraders	23-06-16	MT
GNI Group Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
GNI Group Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year 2023	23-05-15	CI
Beijing Continent Achieves Mid-Point Subject Enrollment for F351 Phase III Clinical Trial in China	23-05-09	CI
GNI : Amendment of "FY2022 difference between forecast and actual" document	23-03-07	PU
GNI Group Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year 2023	23-03-07	CI
GNI : summary Q&A from full-year 2022 financial results analyst call and other recent inquiries	23-03-02	PU
GNI : Consolidated Financial Results for FY2022(IFRS)	23-02-15	PU
GNI Group Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending December 2022	23-02-15	CI
GNI to Take Controlling Stake in Nasdaq-listed Catalyst Biosciences via Liver Fibrosis Drug Development Deals; Shares Up 3%	22-12-27	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights GNI Group Ltd.

Equities

2160

JP3386370005

Highlights

Filters